RXDX News and Press, Prometheus Biosciences Inc. From 08/02/21

- First Anti-TL1A trial in Crohn’s Disease - - APOLLO-CD Phase 2a along with ARTEMIS-UC Phase 2 topline results expected in fourth quarter 2022 - - Final Phase 1a results for PRA023 in normal healthy volunteers expected in fourth quarter 2021- SAN DIEGO, Aug...

solarseven/iStock via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...

Prometheus Biosciences (RXDX) announces the initiation of the Phase 2 ARTEMIS-UC trial evaluating PRA023 for moderate-to-severe ulcerative colitis ((UC)).The company highlighted that the Phase 2a initiation in Crohn’s Disease ((CD)) on track for the third-quarter of 2021.Prom...

-First precision approach to IBD by utilizing a companion diagnostic to identify patients- -Phase 2a initiation in Crohn’s Disease on track for 3 rd Quarter 2021- - Further details to be provided at R&D Day on July 28 th - SAN DIE...

SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the trea...

Mir Basar Suhaib/iStock via Getty Images Recently IPO’ed biotech firms Prometheus Biosciences ([[RXDX]] -21.5%) and Recursion Pharmaceuticals ([[RXRX]] -19.2%) are on course to record their biggest one-day losses since their public debut in March and April, respectively. As demons...

-Prometheus receives $10 million payment triggered by selection of clinical candidate for PR600- -IND for PR600 expected in 3Q 2022- SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a ...

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treat...

Following a gain of ~21.8% yesterday, Prometheus Biosciences ([[RXDX]] +1.8%) is continuing the momentum today in apparent reaction to the appointment of industry veteran Fred Hassan to its board of directors.Mr. Hassan was a former chairman of Bausch & Lomb from 2010 until the ...

SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treat...